162 results on '"McGovern, Barbara H."'
Search Results
2. A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis
3. Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.
4. Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative
5. Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection
6. Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study
7. Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic.
8. Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool
9. Manufacturing Process of Investigational Microbiome Therapeutic, SER-109, Reduces Risk of Bacterial Pathogen Transmission
10. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection
11. Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection—the InC³ Study
12. Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial
13. Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
14. Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
15. Hepatitis C Virus and the Infectious Disease Physician: A Perfect Match
16. SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
17. A "One-Two Punch" Leading to Hepatitis C Seroconversion
18. Improving the Diagnosis of Acute Hepatitis C Virus Infection with Expanded Viral Load Criteria
19. Rate of Sustained Virologic Response in Relation to Baseline Hepatitis C Virus (HCV) RNA Level and Rapid Virologic Clearance in Persons with Acute HCV Infection
20. Underascertainment of Acute Hepatitis C Virus Infections in the U.S. Surveillance System: A Case Series and Chart Review
21. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection
22. Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study
23. Su1873 RESULTS FROM AN OPEN-LABEL STUDY (ECOSPOR IV) TO EVALUATE THE SAFETY AND EFFICACY OF SER-109, AN INVESTIGATIONAL ORAL MICROBIOME THERAPEUTIC, IN ADULTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION (RCDI): A SUBGROUP ANALYSIS
24. 694 DURABILITY OF THE CLINICAL RESPONSE TO SER-109, AN INVESTIGATIONAL ORAL MICROBIOME THERAPEUTIC, IN A PHASE 3 OPEN-LABEL TRIAL (ECOSPOR IV) IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
25. Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon
26. Hepatitis C in the HIV-infected patient
27. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients
28. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients
29. Acute hepatitis C virus infection in incarcerated injection drug users
30. Contributors
31. HIV Co-Infection Drug Toxicity
32. A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users
33. The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridiumdifficile Infection: Current Understanding and Gap Analysis
34. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial
35. Avoiding therapeutic pitfalls: The rational use of specifically targeted agents against hepatitis C infection
36. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
37. Extended Follow-up of Microbiome Therapeutic SER-109 for Recurrent Clostridioides difficile Infection—Reply.
38. Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation
39. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents RecurrentClostridium difficileInfection
40. Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
41. Preface
42. Hepatic Steatosis in HIV/HCV–Coinfected Patients: Time to Reevaluate!
43. Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study.
44. The Epidemiology, Natural History and Prevention of Hepatitis B: Implications of HIV Coinfection
45. Editorial Commentary: Hepatitis C Virus and the Infectious Disease Physician: A Perfect Match.
46. The Impact of Cirrhosis on CD4+ T Cell Counts in HIV-Seronegative Patients.
47. Impact of New Therapeutics for Hepatitis C Virus Infection in Incarcerated Populations.
48. Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study
49. The Epidemiology, Natural History and Prevention of Hepatitis B: Implications of HIV Coinfection
50. Characteristics of HCV-Infected Patients with Cirrhosis Requiring Ribavirin Dose Reduction During Treatment with Direct-Acting Antivirals
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.